Economic dimensions of personalized and precision medicine /
Personalized and precision medicine (PPM) - the targeting of therapies according to an individual's genetic, environmental, or lifestyle characteristics - is becoming an increasingly important approach in health care treatment and prevention. This volume explores the intersection of the scienti...
| Tác giả khác: | , , |
|---|---|
| Định dạng: | Licensed eBooks |
| Ngôn ngữ: | Tiếng Anh |
| Được phát hành: |
Chicago ; London :
The University of Chicago Press,
2019.
|
| Loạt: | National Bureau of Economic Research conference report.
|
| Truy cập trực tuyến: | https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1941135 |
Mục lục:
- Intro; Contents; Acknowledgment; Introduction / Ernst R. Berndt, Dana P. Goldman, and John W. Rowe; 1. The Economic Value and Pricing of Personalized Medicine / Tomas J. Philipson; 2. Therapeutic Translation of Genomic Science: Opportunities and Limitations of GWAS / Manuel Hermosilla and Jorge Lemus; 3. The Value of Pharmacogenomic Information / John A. Graves, Zilu Zhou, Shawn Garbett, and Josh F. Peterson; 4. The Information Pharms Race and Competitive Dynamics of Precision Medicine: Insights from Game Theory / Ernst R. Berndt and Mark R. Trusheim
- 5. Characterizing the Drug Development Pipeline for Precision Medicines / Amitabh Chandra, Craig Garthwaite, and Ariel Dora Stern6. Cost Sharing in Insurance Coverage for Precision Medicine / Mark V. Pauly; 7. Measuring the Potential Health Impact of Personalized Medicine: Evidence from Multiple Sclerosis Treatments / Kristopher J. Hult; 8. Physicians' Financial Incentives to Personalize Medicine / David H. Howard, Jason Hockenberry, and Guy David
- 9. Economic Dimensions of Personalized and Precision Medicine in Asia: Evidence from Breast Cancer Treatment in Taiwan / Jui-fen Rachel Lu, Karen Eggleston, and Joseph Tung-Chieh Chang10. The Value of Cytochrome P450 2C19 Pharmacogenomic Information for Patients Receiving Clopidogrel Therapy Following a Major Cardiovascular Event: Evidence from Geisinger / Rebecca A. Pulk, Jove Graham, Frank R. Lichtenberg, Daniel Maeng, Marc S. Williams, and Eric Wright; 11. Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies / Philippe Gorry and Diego Useche
- ContributorsAuthor Index; Subject Index